A Phase 2 interventional study of PrabotulinumtoxinA-Xvfs and OnabotulinumtoxinA in Glabellar Frown Lines, sponsored by Evolus, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-04.
Sponsored by Evolus, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown lines, which are the vertical lines that develop between the eyebrows) in adult participants. It will also determine if the duration of effect of 40 Units of Jeuveau® is greater than that of 20 Units of Jeuveau® and 20 Units of Botox® Cosmetic.
This is a multicenter, prospective, randomized, double-blind, active-controlled, single-treatment, increasing dose design. Up to one hundred and fifty subjects will be randomized 1:1:1, to either 20 Units onabotulinumtoxinA (Botox® Cosmetic), 20 Units prabotulinumtoxinA-xvfs (Jeuveau®), or 40 Units prabotulinumtoxinA-xvfs (Jeuveau®).
Evolus, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40U of PrabotulinumtoxinA-xvfs
Drug: PrabotulinumtoxinA-Xvfs
20U of OnabotulinumtoxinA
Drug: OnabotulinumtoxinA
20U of PrabotulinumtoxinA-xvfs
Drug: PrabotulinumtoxinA-Xvfs
One treatment of 40 units
Also known as: Jeuveau
One treatment of 20 units
Also known as: Botox Cosmetic
One treatment of 20 units
Also known as: Jeuveau
Duration of Effect Described by Kaplan-Meier Analysis
Effectiveness of prabotulinumtoxinA 40 Units compared to prabotulinumtoxinA 20 Units will be assessed for each subject based on the number of days from baseline to the day that the Glabellar Line Scale (GLS) severity, by Investigator Assessment, returns to the baseline value. The treatment will be considered to remain effective for the amount of time during which the GLS severity at maximum frown has not returned to baseline severity.
Time frame: Duration of effect for each subject will be based on number of days from baseline to the day that Glabellar Line Scale severity (Investigator Assessment) returns to baseline value, assessed every 30 days up to 365 days.
| Milestone | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs |
|---|---|---|---|
| Started | 51 | 50 | 53 |
| Completed | 49 | 48 | 47 |
| Not completed | 2 | 2 | 6 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 |
| Withdrew: Moved; too much driving | 0 | 0 | 2 |
| Withdrew: Did not receive treatment | 0 | 0 | 1 |
Effectiveness of prabotulinumtoxinA 40 Units compared to prabotulinumtoxinA 20 Units will be assessed for each subject based on the number of days from baseline to the day that the Glabellar Line Scale (GLS) severity, by Investigator Assessment, returns to the baseline value. The treatment will be considered to remain effective for the amount of time during which the GLS severity at maximum frown has not returned to baseline severity.
| Days | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs |
|---|---|---|---|
| Duration of Effect Described by Kaplan-Meier Analysis | 183 (153 to 211) | 148 (121 to 174) | 149 (130 to 174) |
Collected over Adverse event data were collected over a period of up 12 months post treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Study Drug | 0/51 (0%) | 0/51 (0%) | 2/51 (3.9%) |
| OnabotulinumtoxinA | 0/50 (0%) | 0/50 (0%) | 5/50 (10%) |
| PrabotulinumtoxinA-xvfs | 0/53 (0%) | 0/53 (0%) | 3/52 (5.8%) |
| Event | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs |
|---|---|---|---|
| COVID-19Infections and infestations | 0/51 | 3/50 | 0/52 |
| HeadacheNervous system disorders | 2/51 | 2/50 | 3/52 |
| Age, Continuous(years) | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs | Total |
|---|---|---|---|---|
| Mean | 46.8 ± 11.3 | 47.0 ± 11.1 | 46.8 ± 12.9 | 47 ± 11.5 |
| Sex: Female, Male(Participants) | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs | Total |
|---|---|---|---|---|
| Female | 48 | 47 | 50 | 145 |
| Male | 3 | 3 | 3 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs | Total |
|---|---|---|---|---|
| Hispanic or Latino | 20 | 16 | 15 | 51 |
| Not Hispanic or Latino | 31 | 34 | 37 | 102 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 3 | 8 |
| White | 48 | 47 | 49 | 144 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs | Total |
|---|---|---|---|---|
| United States | 51 | 50 | 53 | 154 |
| Participant Has a Prior history of botulinum toxin use(Participants) | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs | Total |
|---|---|---|---|---|
| Count of participants | 26 | 26 | 19 | 71 |
| Glabellar Line Score of Moderate at Maximum Frown by Investigator Assessment(Participants) | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs | Total |
|---|---|---|---|---|
| Count of participants | 15 | 14 | 18 | 47 |
| Glabellar Line Score of Moderate at Maximum Frown by Subject Assessment(Participants) | Study Drug | OnabotulinumtoxinA | PrabotulinumtoxinA-xvfs | Total |
|---|---|---|---|---|
| Count of participants | 11 | 7 | 13 | 31 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2022 to primary completion in May 2023, 13 months.
Results were first posted in Sep 2024, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prabotulinumtoxin A
Evolus, Inc.